SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
IRVINE, Calif., March 31, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (Nasdaq:STML). Investors who purchased shares of the Company either (1) pursuant and/or traceable to Stemline’s secondary public offering on or about January 20, 2017; and/or (2) publicly traded on the open market between January 19, 2017 and February 1, 2017 inclusive (the “Class Period”) are encouraged to contact the Firm by the April 4, 2017 lead plaintiff motion deadline.
If you purchased shares of Stemline during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint alleges that during the Class Period, Stemline made false and/or misleading statements and/or failed to disclose that a cancer patient in a Stemline clinical trial tied to SL-401 died from a severe side effect on January 18, 2017; and thus, the Company’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. On February 2, 2017, Bloomberg disclosed that a patient in a clinical trial of Stemline’s cancer drug SL-401 died from a side effect. This is the third death linked to SL-401 toxicity. When this information was announced to the public, the value of Stemline stock fell significantly, causing investors severe harm.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contacts Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
